BOOKS BY CATEGORY
Your Account
Camptothecins in Cancer Therapy
Price
Quantity
£199.50
(To see other currencies, click on price)
Paperback / softback
Add to basket  

MORE ABOUT THIS BOOK

Main description:

A critical review our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.


Back cover:

Clinical interest in the camptothecins continues to expand even though this class of topoisomerase I inhibitors has been studied for almost 50 years, and two early generation members of the family have gained FDA approval. In Camptothecins in Cancer Therapy, leading clinicians and researchers critically review our current understanding of camptothecins, their shortcomings, and the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.

Authoritative and up-to-date, Camptothecins in Cancer Therapy provides a comprehensive summary of camptothecin research, as well as a much-needed guide to all the latest information on their optimal therapeutic applications.


Contents:

Part I: Biochemistry, Pharmacology, and Chemistry

Mechanism of Action of Topoisomerase 1 Poisons
Leroy F. Liu and Shyamal D. Desai

Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage
Alex B. Burgin, Jr., Michael D. Feese, Bart L. Staker, and Lance Stewart

Inhibitors of Topoisomerase I Function
Sidney M. Hecht

Cytotoxic Mechanisms of the Topoisomerase 1 Inhibitors
Yves G. Pommier, Juana Barceló, Takahisa Furuta, Haruyuki Takemura, Olivier Sordet, and ZhiYong Liao

Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage
Robert C. A. M. van Waardenburg and Mary-Ann Bjornsti

Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs
Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, and Peter J. Houghton

Mechanisms of Resistance to Camptothecins
Zeshaan A. Rasheed and Eric H. Rubin

Recent Advances in Camptothecin Drug Design and Delivery Strategies
Thomas G. Burke, Tian-Xiang Xiang, Bradley D. Anderson, and Lori J. Latus

Part II: Clinical Perspectives

Clinical Experience With 9-Aminocamptothecin: Lessons for New Drug Development
Chris H. Takimoto

Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin)
Hilary Hewes, Judith A. Smith, and Claire Verschraegen

Irinotecan: Current Clinical Status and Pharmacological Aspects
Laurent P. Rivory

Clinical Experience With Topotecan
Aimee K. Bence and Val R. Adams

The Clinical Development of Lurtotecan: Experience With Water-Soluble and Liposomal Forms
Keith T. Flaherty, James P. Stevenson, Christopher J. Twelves, and Peter J. O'Dwyer

Preclinical and Clinical Development of Exatecan (DX-8951f): A Hexacyclic Camptothecin Analog
Eric K. Rowinsky

Camptothecins in the Treatment of Primary Brain Tumors
Clinton F. Stewart,Markos Leggas, and Henry S. Friedman

Camptothecins in the Treatment of Lung Cancer
Pankaj Kumar, Missak Haigentz, Jr., Jorge Gomez, and Roman Perez-Soler

Use of Camptothecins in the Treatment of Leukemia and Related Disorders
Benjamin M. F. Mow and Scott H. Kaufmann

Index


PRODUCT DETAILS

ISBN-13: 9781627038164
Publisher: Springer (Humana Press)
Publication date: November, 2014
Pages: 476
Weight: 724g
Availability: POD
Subcategories: Oncology
Related books
From the same series

CUSTOMER REVIEWS

Average Rating 

"...an excellent all-around reference appropriate for researchers or clinicians in anticancer drug literature." - Doody's Health Science Book Review Journal